Literature DB >> 18369590

Back to basics in septic shock.

Mark J Peters, Joe Brierley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18369590     DOI： 10.1007/s00134-008-1086-8

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  18 in total

Review 1.  New strategies for clinical trials in patients with sepsis and septic shock.

Authors:  J Cohen; G Guyatt; G R Bernard; T Calandra; D Cook; D Elbourne; J Marshall; A Nunn; S Opal
Journal:  Crit Care Med       Date:  2001-04       Impact factor: 7.598

Review 2.  Mechanotransduction and endothelial cell homeostasis: the wisdom of the cell.

Authors:  Shu Chien
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-11-10       Impact factor: 4.733

3.  Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure.

Authors:  Tomoko Ono; Jun Mimuro; Seiji Madoiwa; Kenji Soejima; Yuji Kashiwakura; Akira Ishiwata; Katsuhiro Takano; Tsukasa Ohmori; Yoichi Sakata
Journal:  Blood       Date:  2005-09-27       Impact factor: 22.113

4.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock.

Authors:  R C Bone; C J Fisher; T P Clemmer; G J Slotman; C A Metz; R A Balk
Journal:  N Engl J Med       Date:  1987-09-10       Impact factor: 91.245

5.  Sepsis and controlled clinical trials: the odyssey.

Authors:  R C Bone
Journal:  Crit Care Med       Date:  1995-07       Impact factor: 7.598

6.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Authors:  S M Opal; C J Fisher; J F Dhainaut; J L Vincent; R Brase; S F Lowry; J C Sadoff; G J Slotman; H Levy; R A Balk; M P Shelly; J P Pribble; J F LaBrecque; J Lookabaugh; H Donovan; H Dubin; R Baughman; J Norman; E DeMaria; K Matzel; E Abraham; M Seneff
Journal:  Crit Care Med       Date:  1997-07       Impact factor: 7.598

7.  Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group.

Authors:  M Levin; P A Quint; B Goldstein; P Barton; J S Bradley; S D Shemie; T Yeh; S S Kim; D P Cafaro; P J Scannon; B P Giroir
Journal:  Lancet       Date:  2000-09-16       Impact factor: 79.321

Review 8.  Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock.

Authors:  Joseph A Carcillo; Alan I Fields
Journal:  Crit Care Med       Date:  2002-06       Impact factor: 7.598

9.  The influence of early hemodynamic optimization on biomarker patterns of severe sepsis and septic shock.

Authors:  Emanuel P Rivers; James A Kruse; Gordon Jacobsen; Kant Shah; Manisha Loomba; Ronny Otero; Ed W Childs
Journal:  Crit Care Med       Date:  2007-09       Impact factor: 7.598

10.  ACCM/PALS haemodynamic support guidelines for paediatric septic shock: an outcomes comparison with and without monitoring central venous oxygen saturation.

Authors:  Cláudio F de Oliveira; Débora S F de Oliveira; Adriana F C Gottschald; Juliana D G Moura; Graziela A Costa; Andréa C Ventura; José Carlos Fernandes; Flávio A C Vaz; Joseph A Carcillo; Emanuel P Rivers; Eduardo J Troster
Journal:  Intensive Care Med       Date:  2008-03-28       Impact factor: 17.440
View more
  2 in total

1.  Evolution of haemodynamics and outcome of fluid-refractory septic shock in children.

Authors:  Akash Deep; Chulananda D A Goonasekera; Yanzhong Wang; Joe Brierley
Journal:  Intensive Care Med       Date:  2013-06-28       Impact factor: 17.440

2.  Fluid management in the critically ill child.

Authors:  Sainath Raman; Mark J Peters
Journal:  Pediatr Nephrol       Date:  2013-01-30       Impact factor: 3.714
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.